Additionally, novel strategies like reprogramming TAMs or leveraging chimeric antigen receptor macrophages (CAR-M) in conjunction with Gal-9 inhibition could further disrupt the immunosuppressive TME and stimulate anti-tumor immunity. The gene discussed is LGALS9; the disease is neoplasm.